SARS-CoV-2 NeutraLISA by EUROIMMUN
Manufacturer EUROIMMUN | Available Worldwide
The SARS-CoV-2 NeutraLISA provides fast and economical determination of the inhibiting effect of anti-SARS-CoV-2 antibodies in patient samples, serving as a surrogate virus neutralisation test. The assay is based on competitive binding between neutralising antibodies in the samples and labelled ACE2 receptors to S1/RBD. The test supports evaluation of the immune response following SARS-CoV-2 infection or vaccination.
SARS-CoV-2 NeutraLISA
- Surrogate virus neutralisation test (sVNT) for determination of neutralising antibodies that inhibit the binding of SARS-CoV-2 S1/RBD to ACE2 receptors
- Very good (98.6%) agreement of results in comparison with the plaque reduction neutralisation test (PRNT50)
- Established ELISA method –suitable for routine diagnostics, no BSL-3 conditions required
- Automatable even for high-throughput analyses, results available in 2 hour
- CE marked
Product Overview
SARS-CoV-2 NeutraLISA
Manufacturer EUROIMMUN | Available Worldwide
Be the first to review this product
